Medicinal Chemistry Spring Symposium 2017
Immunotherapy is generating strong excitement in the scientific community and in the clinic. For example, the recent development and clinical success of checkpoint inhibitors (PD-1 and CTLA-4), bispecifics (T-cell engagement) and T-cell replacement therapies has led to significantly improved therapies and new hope for many cancer patients. Currently available immuno-oncology therapeutics are mostly biologics (antibodies, proteins, engineered cells and oncolytic viruses). Modulation of the immune system with small molecules may offer several complementary and potentially synergistic advantages to the use of large biologicals. The latter is a strong stimulus for the development of novel small-molecule modulators by medicinal chemists working in cancer immunotherapy. This symposium will provide a bird’s eye perspective on the developments in immuno-oncology, from large biologics to small molecules. Recent immunotherapy approaches that will be presented include checkpoint inhibition, IDO/TDO targeting, bispecifics, dendritic cell therapy and vaccination, in lectures delivered by several of the frontrunners in this rapidly evolving and exciting field.
Date: March 17, 2017
Location: Boothzaal, University library
Heidelberglaan 3
3584 CS Utrecht
(Route)
